Cartinex Tablets (Ranolazine)

• Composition :
  Each SR Tablet contains Ranolazine 500mg.
• Indications :
  For the treatment of chronic angina.
• Pharmacodynamics :
  Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (INa). However, the relationship of this inhibition to angina symptoms is uncertain.
• Dosage and administration :
  500 mg twice daily and increase to 1000 mg twice daily, based on clinical symptoms.
• Contraindications :
  In patients with liver cirrhosis. Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, Nelfinavir. CYP3A inducers (e.g., rifampin, phenobarbital)
• Precautions and warnings :
  QT interval prolongation can occur with Ranolazine. Caution should be exercised when administered to patients with renal impairment.
• Use in pregnancy, lactation & pediatrics :
  There are no data available on Ranolazine use in pregnant and nursing women. should not be used during pregnancy and breast feeding. Safety and efficacy in pediatric patients is not established.
• Drug interactions :
  Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ranolazine to 500 mg twice daily. P-gp inhibitors (e.g., cyclosporine): Ranolazine exposure increased. Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ranolazine.
• Adverse reactions :
  Dizziness, headache, constipation and nausea.
• Therapy Area :
  Anti-Anginals